Search results
Showing 1101 to 1150 of 1328 results for nice quality standards or clinical guidelines
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence in mammography .
Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.
Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.
Balloon cryoablation for squamous dysplasia of the oesophagus (HTG560)
Evidence-based recommendations on balloon cryoablation for squamous dysplasia of the oesophagus. This involves using a balloon filled with cold gas to destroy abnormal cells.
View recommendations for HTG560Show all sections
Evidence-based recommendations on SecurAcath for securing percutaneous catheters.
PredictSURE IBD and IBDX to guide treatment of Crohn's disease (HTG610)
Evidence-based recommendations on PredictSURE IBD and IBDX for guiding treatment of Crohn’s disease.
Evidence-based recommendations on bempedoic acid with ezetimibe (Nilemdo and Nustendi) for treating primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet in adults.
HemaClear for bloodless surgical field during limb surgery (MIB187)
NICE has developed a medtech innovation briefing (MIB) on HemaClear for bloodless surgical field during limb surgery .
NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional
Tell us what matters to you, your organisation or your community.
Tell us what matters to you, your organisation or your community.
Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain (HTG652)
Evidence-based recommendations on percutaneous image-guided cryoablation of peripheral neuroma for chronic pain. This involves using a needle-like probe to freeze and destroy small parts of nerves in neuromas to stop the pain signals.
View recommendations for HTG652Show all sections
Our modular updates framework ensures flexibility and consistency in updating our manuals and helps prioritise important updates.
C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)
Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making
Transcranial MRI-guided focused ultrasound thalamotomy for neuropathic pain (HTG491)
Evidence-based recommendations on transcranial MRI-guided focused ultrasound thalamotomy for neuropathic pain in adults. This involves delivering focused ultrasound to a small part of the brain (in the thalamus) responsible for transmitting pain signals to destroy it.
View recommendations for HTG491Show all sections
Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)
This interim process statement sets out to guide the development of 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs). It provides an overview of the key process principles and describes all stages of development for ESUOMs
Evidence-based recommendations on everolimus (Afinitor) and sunitinib (Sutent) for treating neuroendocrine tumours in adults.
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older.
Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.
Evidence-based recommendations on implantation of a shock or load absorber for mild to moderate symptomatic medial knee osteoarthritis.
Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.
This indicator covers under 75 mortality from liver disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)
NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .
How to register with us as a medical technologies stakeholder.
How to register with us as a medical technologies stakeholder.
This indicator covers under 75 mortality from respiratory disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee
Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.
Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure.
Evidence-based recommendations on transvaginal laser therapy for urogenital atrophy. This involves using a laser in the vagina to increase its strength and elasticity, to improve symptoms of urogenital atrophy.
View recommendations for HTG582Show all sections
Transvaginal laser therapy for stress urinary incontinence (HTG581)
Evidence-based recommendations on transvaginal laser therapy for urinary stress incontinence. This involves using a laser in the vagina to strengthen the vaginal walls, to help support the bladder and reduce symptoms of urinary stress incontinence.
View recommendations for HTG581Show all sections
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults.
"position":2,"item":{"@id":"/about-us","name":"About us"}}]} Structure of NICE NICE is an organisation made up of people...
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome in people aged 2 years and older.
Brodalumab for treating moderate to severe plaque psoriasis (TA511)
Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway.
The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma (MIB8)
NICE has developed a Medtech Innovation Briefing (MIB) on the Airsonett temperature-controlled laminar airflow device for persistent allergic asthma
Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults.
Evidence-based recommendations on short-term circulatory support with left ventricular assist devices (LVAD) as a bridge to heart transplantation or recovery. This involves inserting a mechanical device into the chest to help the heart pump blood around the body.
View recommendations for HTG115Show all sections
Sections for HTG115
How to register with us as a diagnostic technologies stakeholder.
How to register with us as a diagnostic technologies stakeholder.
Late stage assessment (LSA) guidance on transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis.
View recommendations for HTG757Show all sections
CareLink network service for remote monitoring of people with cardiac devices (MIB64)
NICE has developed a medtech innovation briefing (MIB) on the CareLink network service for remote monitoring of people with cardiac devices
BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume (MIB50)
NICE has developed a medtech innovation briefing (MIB) on the BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume
This indicator covers tooth extractions due to decay for children admitted as inpatients to hospital, aged 10 years and under. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
NICE has developed a medtech innovation briefing (MIB) on plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer .
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.
Show all sections
Obeticholic acid for treating primary biliary cholangitis (TA443)
Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis in adults.